Pasar al contenido principal

EFICACIA Y SEGURIDAD DE LA FUROSEMIDA INTRAVENOSA ADMINISTRADA CON SUERO SALINO HIPERTONICO EN EL HOSPITAL DE DIA DE INSUFICIENCIA CARDIACA.

PI20/00689

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL HOSPITAL UNIV. PUERTA DE HIERRO MAJADAHONDA (IDIPHIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design and baseline characteristics of SALT-HF trial, hypertonic saline therapy in ambulatory heart failure

  • Cobo Marcos, M.
  • Comín-Colet, Josep|||0000-0001-8780-720X
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Rubio Gracia, J.
  • Morales-Rull, J.L.
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • Llacer, P.
  • Diez-Villanueva, P.
  • Jiménez-Marrero, S.
  • de Juan Bagudá, J.
  • Ortiz Cortés, C.
  • Goirigolzarri-Artaza, J.
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Barrios, E.
  • del Prado Díaz, S.
  • Montero Hernández, E.
  • Sanchez-Marteles, M.
  • Nuñez, J.
Hypertonic saline solution (HSS) plus intravenous (IV) loop diuretic appears to enhance the diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this therapy in the ambulatory setting have not been evaluated. We aimed to describe the design and baseline characteristics of the SALT-HF trial participants. 'Efficacy of Saline Hypertonic Therapy in Ambulatory Patients with HF' (SALT-HF) trial was a multicenter, double-blinded, and randomized study involving ambulatory patients who experienced worsening heart failure (WHF) without criteria for hospitalization. Enrolled patients had to present at least two signs of volume overload, use ≥ 80 mg of oral furosemide daily, and have elevated natriuretic peptides. Patients were randomized 1:1 to treatment with a 1-h infusion of IV furosemide plus HSS (2.6-3.4% NaCl depending on plasmatic sodium levels) versus a 1-h infusion of IV furosemide at the same dose (125-250 mg, depending on basal loop diuretic dose). Clinical, laboratory, and imaging parameters were collected at baseline and after 7 days, and a telephone visit was planned after 30 days. The primary endpoint was 3-h diuresis after treatment started. Secondary endpoints included (a) 7-day changes in congestion data, (b) 7-day changes in kidney function and electrolytes, (c) 30-day clinical events (need of IV diuretic, HF hospitalization, cardiovascular mortality, all-cause mortality or HF-hospitalization). A total of 167 participants [median age, 81 years; interquartile range (IQR), 73-87, 30.5% females] were randomized across 13 sites between December 2020 and March 2023. Half of the participants (n = 82) had an ejection fraction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure

  • Cobo Marcos, M.
  • Comín-Colet, J.
  • de la Espriella, R.
  • Rubio Gracia, J.
  • Morales-Rull, J.L.
  • Zegrí, I.
  • Llacer, P.
  • Diez-Villanueva, P.
  • Jiménez-Marrero, S.
  • de Juan Bagudá, J.
  • Ortiz Cortés, C.
  • Goirigolzarri-Artaza, J.
  • García-Pinilla, J.M.
  • Barrios, E.
  • del Prado Díaz, S.
  • Montero Hernández, E.
  • Sanchez-Marteles, M.
  • Nuñez, J.
Aims: Hypertonic saline solution (HSS) plus intravenous (IV) loop diuretic appears to enhance the diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this therapy in the ambulatory setting have not been evaluated. We aimed to describe the design and baseline characteristics of the SALT-HF trial participants. Methods and results: ‘Efficacy of Saline Hypertonic Therapy in Ambulatory Patients with HF’ (SALT-HF) trial was a multicenter, double-blinded, and randomized study involving ambulatory patients who experienced worsening heart failure (WHF) without criteria for hospitalization. Enrolled patients had to present at least two signs of volume overload, use ≥ 80 mg of oral furosemide daily, and have elevated natriuretic peptides. Patients were randomized 1:1 to treatment with a 1-h infusion of IV furosemide plus HSS (2.6–3.4% NaCl depending on plasmatic sodium levels) versus a 1-h infusion of IV furosemide at the same dose (125–250 mg, depending on basal loop diuretic dose). Clinical, laboratory, and imaging parameters were collected at baseline and after 7 days, and a telephone visit was planned after 30 days. The primary endpoint was 3-h diuresis after treatment started. Secondary endpoints included (a) 7-day changes in congestion data, (b) 7-day changes in kidney function and electrolytes, (c) 30-day clinical events (need of IV diuretic, HF hospitalization, cardiovascular mortality, all-cause mortality or HF-hospitalization). Results: A total of 167 participants [median age, 81 years; interquartile range (IQR), 73–87, 30.5% females] were randomized across 13 sites between December 2020 and March 2023. Half of the participants (n = 82) had an ejection fraction >50%. Most patients showed a high burden of comorbidities, with a median Charlson index of 3 (IQR: 2–4). Common co-morbidities included diabetes mellitus (41%, n = 69), atrial fibrillation (80%, n = 134), and chronic kidney disease (64%, n = 107). Patients exhibited a poor functional NYHA class (69% presenting NYHA III) and several signs of congestion. The mean composite congestion score was 4.3 (standard deviation: 1.7). Ninety per cent of the patients (n = 151) presented oedema and jugular engorgement, and 71% (n = 118) showed lung B lines assessed by ultrasound. Median inferior vena cava diameter was 23 mm, (IQR: 21–25), and plasmatic levels of N-terminal-pro-B-type natriuretic peptide (NTproBNP) and antigen carbohydrate 125 (CA125) were increased (median NT-proBNP 4969 pg/mL, IQR: 2508–9328; median CA125 46 U/L, IQR: 20–114). Conclusions: SALT-HF trial randomized 167 ambulatory patients with WHF and will determine whether an infusion of hypertonic saline therapy plus furosemide increases diuresis and improves decongestion compared to equivalent furosemide administration alone.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: The SALT-HF trial

  • Cobo Marcos, Marta
  • de la Espriella, Rafael
  • Comín-Colet, Josep
  • Zegrí-Reiriz, Isabel
  • Rubio Gracia, Jorge
  • Morales-Rull, Jose Luis
  • Llàcer, Pau
  • Díez-Villanueva, Pablo
  • Jiménez-Marrero, Santiago
  • de Juan Bagudá, Javier
  • Ortiz Cortés, Carolina
  • Restrepo-Córdoba, Maria Alejandra
  • Goirigolzarri-Artaza, Josebe
  • García-Pinilla, Jose Manuel
  • Barrios, Elvira
  • del Prado Díaz, Susana
  • Montero Hernández, Esther
  • Sanchez-Marteles, Marta
  • Núñez, Julio
AimsCombination of hypertonic saline solution (HSS) with intravenous loop diuretics has been suggested to improve diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this approach in the ambulatory setting remain unexplored.Methods and resultsIn this multicentre, double‐blind, randomized study, we allocated ambulatory patients with worsening heart failure (WHF) to a 1‐h infusion of intravenous furosemide (ivFurosemide)‐HSS versus ivFurosemide. The primary endpoint was the volume of diuresis at 3 h. Secondary endpoints included 3‐h natriuresis and weight variation, 7‐day congestion data, kidney function and electrolytes, and 30‐day clinical events. Overall, 167 participants (median age: 81 years, 30.5% female) were randomized across 13 sites between December 2020 and March 2023. There were no differences in 3‐h diuresis between treatments (ivFurosemide‐HSS: 1099 ml vs. ivFurosemide: 1103 ml, p = 0.963), 3‐h natriuresis (∆ +2.642 mEq/L, p = 0.559), or 3‐h weight (∆ +0.012 kg, p = 0.920). Patients in the ivFurosemide‐HSS arm experienced significant weight decrease at 7 days (Δ −0.586 kg, p = 0.048). There were no between‐treatment differences in clinical congestion score, biomarkers, inferior vena cava diameter, or the presence of lung ultrasound B‐lines. At 30 days, 26.5% of the patients in the ivFurosemide‐HSS group versus 33.3% in the ivFurosemide group experienced WHF (hazard ratio 0.76, p = 0.330). The incidence of death from any cause or HF hospitalization was 6% of patients in the ivFurosemide‐HSS group and 8.3% of patients in the ivFurosemide group (hazard ratio 0.69, p = 0.521). The incidence of worsening kidney function or metabolic derangements was not significantly different in the two arms.ConclusionsA single infusion of ivFurosemide‐HSS did not improve 3‐h diuresis or congestion parameters in patients with ambulatory WHF. This therapy showed an appropriate safety profile.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Salt repletion and diuretic response: The role of serum chloride. A post-hoc analysis of the <scp>SALT</scp>-<scp>HF</scp> trial on furosemide and hypertonic saline solution administration in ambulatory patients with worsening heart failure

  • Núñez, Julio
  • Miñana, Gema
  • de la Espriella, Rafael
  • Zegrí-Reiriz, Isabel
  • Comín-Colet, Josep
  • Rubio Gracia, Jorge
  • Morales-Rull, Jose Luis
  • Llàcer, Pau
  • Diez-Villanueva, Pablo
  • de Juan Bagudá, Javier
  • Ortiz Cortés, Carolina
  • Goirigolzarri-Artaza, Josebe
  • García-Pinilla, Jose Manuel
  • Barrios, Elvira
  • del Prado Díaz, Susana
  • Jiménez-Marrero, Santiago
  • Restrepo-Córdoba, Maria Alejandra
  • Testani, Jeffrey
  • Cobo Marcos, Marta
Aims The efficacy of combining hypertonic saline solution (HSS) with loop diuretics in worsening heart failure (WHF) remains uncertain. Hypochloraemia has been associated with reduced diuretic efficacy. Some authors propose that chloride repletion may enhance natriuretic and diuretic responses. This post-hoc analysis of the SALT-HF trial evaluated the effect of single-dose administration of HSS plus intravenous (IV) furosemide versus IV furosemide, stratified by baseline serum chloride. Methods and results The analysis included 148 ambulatory patients with WHF from the double-blind, randomized SALT-HF trial. Participants received either an IV single dose of HSS plus furosemide or IV furosemide. The endpoints were 3-h urinary sodium excretion and diuresis, 7-day congestion score, and 30-day adverse events according to chloride levels. Multivariable linear and logistic regression models assessed the relationship between the intervention and the endpoints. The mean baseline serum chloride level was 100 ± 4 mmol/L. Sixteen patients (10.8%) were identified as hypochloraemic (serum chloride <96 mmol/L), balanced between treatment groups. Patients with hypochloraemia showed a lower natriuretic response (p < 0.05). Interaction analysis revealed a between-treatment differential natriuretic effect based on the chloride levels (pinteraction = 0.008). HSS plus furosemide increased natriuresis compared to furosemide at lower chloride levels. No differential between-treatment effect was found for 3-h diuresis. Similar heterogeneous results were found for the 7-day clinical congestion score and 30-day heart failure events, with a benefit with HSS in patients with lower chloride levels. Conclusion In ambulatory patients with WHF and hypochloraemia, adding HSS to furosemide may improve short-term natriuretic response and outcomes. These findings suggest that chloride supplementation may help overcome diuretic resistance in these patients.